Large CapHealthcareDividend

GILD — Gilead Sciences, Inc.

Biotechnology · Founded 1987 · Foster City, California · CEO: Daniel O'Day

Gilead Sciences is a biopharmaceutical company specializing in antiviral drugs, particularly for HIV, hepatitis, and COVID-19. Its HIV franchise (Biktarvy, Descovy, Genvoya, Truvada) dominates the global HIV treatment market and generates billions in annual revenue. Gilead's hepatitis C drugs (Harvoni, Sovaldi) effectively cured the disease and transformed the treatment paradigm, though that market has since contracted as the curable population has been treated. Gilead is expanding into oncology through its Kite Pharma (CAR-T cell therapy) platform.

How Gilead Sciences, Inc. Makes Money

HIV treatment franchise (Biktarvy, Descovy, Genvoya) provides dominant, recurring pharmaceutical revenue

Veklury (remdesivir) COVID treatment revenue, which has become a more modest, endemic-level product

Kite Pharma CAR-T cell therapy (Yescarta, Tecartus) in hematologic malignancies

Oncology and inflammation pipeline milestone and royalty revenue

Key Metrics Investors Watch

HIV franchise total revenue and patient market share
Biktarvy uptake and persistence as the HIV market evolves
Kite CAR-T revenue and center activation growth
Pipeline progression in oncology and inflammation
Dividend coverage from free cash flow

Competitive Advantages

HIV treatment duopoly with ViiV Healthcare (GSK subsidiary) and dominant market share in the U.S.
Biktarvy is the #1 prescribed HIV treatment globally with strong once-daily single-tablet regimen
Kite Pharma is a leading CAR-T cell therapy platform with approved products and manufacturing expertise
Deep antiviral expertise and nucleotide chemistry know-how provide platform for future antivirals

Key Risks

HIV franchise dependent on patent protection and U.S. government pricing negotiations
Hepatitis C market has matured, removing a major historical growth engine
CAR-T faces competition from Bristol-Myers Squibb (Breyanzi, Abecma) and Novartis (Kymriah)
Lenacapavir (long-acting HIV injection) adoption faces payer and distribution challenges

Dividend & Capital Return

Gilead pays a healthy quarterly dividend and has grown it consistently, supported by the highly predictable HIV franchise cash flows.

I Document Every Trade — Even the Losses

Options record: 1W-8L. Net worth: 100% GSE preferred. Get the unfiltered updates.

Unsubscribe anytime. I respect your inbox more than Congress respects property rights.

Frequently Asked Questions

What is Biktarvy?

Biktarvy is Gilead's flagship once-daily single-tablet HIV treatment combining three antivirals in one pill. It became the most prescribed HIV treatment in the United States shortly after launch and drives the majority of Gilead's HIV franchise revenue. This is educational content, not financial advice.

Did Gilead cure hepatitis C?

Gilead's Sovaldi and Harvoni effectively cured chronic hepatitis C with 8-12 week courses in 95%+ of patients, a revolutionary advance over previous treatments. However, curing most of the treatable population has significantly reduced the recurring hepatitis C market over time. This is educational content, not financial advice.

Does Gilead pay a dividend?

Yes, Gilead pays a quarterly dividend that has grown consistently. The HIV franchise generates strong, predictable cash flows that support the dividend and ongoing share repurchases. This is educational content, not financial advice.

What is Kite Pharma?

Kite Pharma, acquired by Gilead in 2017 for $11.9 billion, is Gilead's CAR-T cell therapy division. Kite's Yescarta and Tecartus products are approved for aggressive blood cancers, representing Gilead's push beyond antivirals into oncology. This is educational content, not financial advice.

Is Gilead a good dividend stock?

Gilead offers a higher dividend yield than most biotech/pharma peers due to its mature HIV franchise generating very predictable cash flows. Investors weigh the HIV moat against limited top-line growth and the evolving pipeline of new therapeutic areas. This is educational content, not financial advice.

Related Stocks

ABBV

AbbVie Inc.

Healthcare

AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and eye care. Spun off from Abbott Laboratories in 2013, AbbVie is best known for Humira (the world's best-selling drug of all time) and its successor drugs Skyrizi and Rinvoq.

MRK

Merck & Co., Inc.

Healthcare

Merck is a global pharmaceutical and animal health company known for Keytruda, the world's best-selling cancer immunotherapy drug. The company has a strong pipeline in oncology, vaccines, and cardiometabolic diseases and operates one of the largest animal health businesses globally.

AMGN

Amgen Inc.

Healthcare

Amgen is one of the world's largest biotechnology companies, pioneering the use of recombinant DNA technology to develop medicines for serious illnesses. Its portfolio spans oncology (Blincyto, Lumakras), cardiovascular (Repatha), bone health (Prolia, XGEVA), and inflammatory diseases (Otezla, Enbrel). Amgen has been expanding into biosimilars and acquired Horizon Therapeutics in 2023 to add rare disease therapies. The company generates among the highest profit margins in the pharmaceutical industry.

BIIB

Biogen Inc.

Healthcare

Biogen is a biotechnology company specializing in neuroscience, with a legacy portfolio in multiple sclerosis (MS) and expanding into Alzheimer's disease, ALS, and neuropsychiatric disorders. The company's multiple sclerosis drugs (Tecfidera, Tysabri, Avonex, Vumerity) built its revenue base. Biogen attracted significant controversy and attention with Aduhelm and then Leqembi (lecanemab), its Alzheimer's treatments developed in partnership with Eisai. Leqembi received full FDA approval in 2023 and represents Biogen's most significant near-term growth opportunity.

MRNA

Moderna, Inc.

Healthcare

Moderna is a biotechnology company that pioneered messenger RNA (mRNA) therapeutics and vaccines. Its COVID-19 vaccine (Spikevax) was authorized in December 2020 and became one of the best-selling pharmaceutical products in history. Post-pandemic, Moderna is deploying its mRNA platform to develop vaccines for respiratory viruses (RSV, flu-COVID combination), personalized cancer vaccines (with Merck), and rare diseases. The company is in a critical transition from COVID dependence to a diversified pipeline.

Recommended Resources

Tools & books I actually use and recommend

SeekingAlpha Premium

Quant ratings, earnings transcripts, and the stock analysis community where I published 300+ articles.

Try SeekingAlpha

The Intelligent Investor

Ben Graham's timeless guide to value investing. The book Warren Buffett calls "the best investing book ever written."

View on Amazon

Interactive Brokers

Low commissions, global market access, and professional-grade tools. This is where I hold my positions.

Open an Account

Some links above are affiliate links. I only recommend products I personally use. See my full disclosures.

Keep Exploring

Hub

All Stocks

Browse all 134 stock profiles by sector.

Best Stocks For Beginners

Curated stock picks for new investors by goal.

Financial Glossary

Understand the terms investors use every day.

Stock vs ETF

Individual stocks vs ETFs — which is right for you?

ETF Profiles

Deep dives on 90+ ETFs across every category.

Buying Your First Stock

How to open a brokerage and buy your first share.

Browse All 134 Stock Profiles

Company information is based on publicly available disclosures and widely-known business facts. No specific price, earnings, or real-time market data is included. This is educational content — not investment advice.